Clients contemplating the sale of their company, a business unit, or selected assets benefit from ConAlliance’s extensive experience in executing divestitures - including structured bilateral sales and competitive auction processes.

We advise shareholders and boards throughout the entire sell-side lifecycle - from equity story development and preparation of marketing materials to buyer identification, global investor outreach, due diligence management, negotiation, and transaction execution. Our objective is clear: maximize valuation, optimize transaction terms, and ensure execution certainty.

Where appropriate, we also assess and structure strategic and financial alternatives to an outright sale - including recapitalizations, minority investments, spin-offs, carve-outs, split-offs, and tracking stock structures - always guided by capital structure efficiency and shareholder value considerations.

Explore our Sell-side Services

ConAlliance advises on acquisitions as an integral component of a company’s current and long-term growth strategy. We support our clients across the full buy-side transaction lifecycle - from strategic target screening and proprietary deal sourcing to valuation, due diligence coordination, bid strategy, negotiation, and global transaction execution.

Our advisory services include structured information gathering, comprehensive target evaluation, synergy modelling, preparation of investment and project memoranda, and financial analysis including optimal transaction structuring. We further support clients in post-merger integration planning to ensure that anticipated value creation and operational synergies are fully realized.

Explore our Buy-side Services

Succession planning is a structured process to transfer leadership and/or ownership of a company in a controlled and value-preserving manner. While particularly critical in family-owned and founder-led businesses, succession planning is equally relevant for partnerships, shareholder groups, and privately held mid-cap companies.

A well-designed succession strategy safeguards enterprise value, ensures operational continuity, and mitigates governance, tax, and capital structure risks associated with a change in control.

ConAlliance advises shareholders and management teams across the entire succession lifecycle - from defining strategic succession alternatives (internal transfer, management buyout, external sale, minority participation, or staged transition) to successor identification and preparation, transaction structuring, valuation, due diligence coordination, negotiation of key commercial terms and purchase agreements, and stakeholder communication.

We integrate financial modelling, capital structure optimization, and continuity planning to ensure a seamless transition and long-term stability of the business. Legal advice is provided in close coordination with external counsel.

Explore our Services in Succession Planning

The sale and licensing of patents and proprietary technologies are central value drivers in the Healthcare and Life Sciences sector. Intellectual property frequently constitutes the core asset base of pharmaceutical, medical technology, biotech, and digital health companies.

Structured IP transactions enable companies to monetize R&D investments, optimize capital allocation, and unlock non-dilutive funding through milestone payments, royalty streams, and territorial licensing structures. In an environment characterized by innovation cycles, regulatory barriers, and lifecycle management considerations, the strategic deployment of IP rights directly impacts valuation and competitive positioning.

ConAlliance advises on the divestiture, licensing, and strategic commercialization of patents and technologies - including valuation of IP portfolios, structuring of royalty and milestone frameworks, negotiation of exclusivity and field-of-use provisions, and alignment with long-term portfolio strategy.

Explore our Services in Patent and Technology Transactions

External growth strategies extend beyond traditional M&A. Strategic alliances, joint ventures, and licensing structures often represent capital-efficient alternatives to full acquisitions and can offer superior risk-adjusted returns depending on the strategic objective.

M&A, joint ventures, and strategic alliances are all instruments of external development. The optimal structure depends on control requirements, capital deployment, risk allocation, speed to market, and long-term value capture. ConAlliance evaluates these alternatives rigorously - drawing on transaction cost economics, resource-based considerations, and financial return modelling - to determine the structure that maximizes strategic flexibility and economic value.

In Healthcare and Life Sciences, trademark, product, and brand licensing structures are particularly prevalent. We advise licensors and licensees on structuring distribution rights, territorial exclusivity, royalty frameworks, and performance covenants to ensure alignment of incentives and long-term commercial success.

Explore our services in the context of cooperations and licensing transactions

A management buyout - MBO - is a transaction in which the incumbent management team acquires a controlling stake in the company, typically to ensure strategic continuity and align ownership with operational leadership.

A management buy-in - MBI - occurs when an external management team acquires a company and assumes executive control, often to unlock untapped operational or strategic potential.

A leveraged buyout - LBO - is the acquisition of a company using a substantial proportion of debt capital. The transaction structure is designed to enhance equity returns through financial leverage, disciplined cash flow management, and value creation initiatives.

ConAlliance provides end-to-end transaction advisory across buy-in and buyout situations - including transaction structuring, capital sourcing, investor syndication, financial modelling, due diligence coordination, and negotiation strategy.

Explore our services in the context of Buy-in and Buyout transactions.

Special situations in M&A involve complex, high-stakes transactions that require strategic precision, capital markets expertise, and disciplined execution.

These include public takeovers, corporate takeover defense mandates, squeeze-outs and minority buyouts, debt and equity restructurings, recapitalizations, and other transformative transactions executed under heightened regulatory, shareholder, or market scrutiny.

ConAlliance advises boards, shareholders, and investors in navigating these situations - structuring defensible transaction frameworks, managing stakeholder communications, coordinating regulatory processes, and optimizing capital structures to safeguard control, valuation, and strategic optionality.

Explore our services in the context of special situations in M&A

Acquisition target screening is a mission-critical element of any Healthcare M&A strategy. In a sector defined by regulatory complexity, reimbursement dynamics, clinical validation, and intellectual property protection, identifying the right target requires far more than financial screening.

ConAlliance integrates strategic fit analysis with healthcare-specific diligence criteria - including reimbursement frameworks, payer mix exposure, regulatory pathway risk, clinical pipeline robustness, patent life cycles, market access positioning, and scalability across healthcare systems.

Our screening methodology combines sector intelligence, scientific and regulatory assessment, financial benchmarking, and preliminary valuation modelling to identify targets that offer defensible competitive advantages and sustainable cash flow visibility.

Whether in pharmaceuticals, medical technology, diagnostics, digital health, or healthcare services, we focus on opportunities where synergies are operationally executable, reimbursement-secured, and strategically aligned with long-term portfolio objectives.

The result: a disciplined shortlisting process that reduces execution risk, strengthens negotiating leverage, and enhances risk-adjusted return on invested capital.

Explore our Services in Acquisition Target Screening